




UK Health
Security
Agency

UK Standards for Microbiology Investigations

Identification of Haemophilus species and the HACEK group of organisms



National Institute for Health and Care Excellence (NICE) has renewed accreditation of the process used by the UK Health Security Agency to produce UK Standards for Microbiology Investigations (UK SMIs). The renewed accreditation is valid until 30 June 2026 and applies to guidance produced using the processes described in 'UK Standards for Microbiology Investigations Development Process' (2021). The original accreditation term began on 1 July 2011.

Acknowledgments

UK Standards for Microbiology Investigations (UK SMIs) are developed under the auspices of UKHSA working in partnership with the partner organisations whose logos are displayed below and listed on [the UK SMI website](#). UK SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see the [Steering Committee section on the RCPATH website](#)).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the medical editors for editing the medical content.

UK SMIs are produced in association with:



Displayed logos correct as of December 2023

Contents

Acknowledgments	2
Contents	3
Amendment table	4
1 General information.....	5
2 Scientific information	5
3 Scope of document	5
4 Introduction.....	6
5 Technical information and limitations.....	8
6 Safety considerations	8
7 Target organisms.....	9
8 Identification	9
9 Storage.....	15
10 Reporting	16
11 Referral to reference or specialist laboratories.....	17
Algorithm A: Identification of HACEK Species	18
Algorithm B: Identification of Haemophilus species.....	19
Algorithm C: Identification of other HACEK organisms.....	20
References	21

Consultation between 07 May 2024 to 24 May 2024

Amendment table

Each UK SMI document has an individual record of amendments. The amendments are listed on this page. The amendment history is available from standards@ukhsa.gov.uk.

Any alterations to this document should be controlled in accordance with the local document control process.

Amendment number/date	x/dd.mm.yy
Issue number discarded	
Insert issue number	
Anticipated next review date*	dd.mm.yy
Section(s) involved	Amendment

*Reviews can be extended up to 5 years where appropriate

Consultation between 01 May 2024 to 24 May 2024

1 General information

[View general information](#) related to UK SMIs.

2 Scientific information

[View scientific information](#) related to UK SMIs.

3 Scope of document

This UK Standards for Microbiology Investigations (UK SMI) document describes the identification of Haemophilus species and other members of the HACEK group of organisms (Aggregatibacter, Cardiobacterium, Eikenella and Kingella species). It includes culture, Gram stain and matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) for the identification of microorganisms from culture. Some biochemical tests may not be done routinely in laboratory except in cases where confirmation by an alternative technique is required or automated methods are not available.

The test procedure for matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) is covered in [UK SMI TP 40: Matrix-assisted laser desorption/ionisation - time of flight mass spectrometry \(MALDI-TOF MS\) test procedure](#). It also includes molecular methods for alternative identification and confirmation

This document mentions the differentiation of Kingella species from pathogenic Neisseria and Morexalla species. The identification of these genera are covered in [UK SMI ID 6: Identification of Neisseria species](#) and [UK SMI ID 11: Identification of Morexalla species and morphologically similar organisms](#).

The direct identification of microorganisms from samples is beyond the scope of this document. For information related to direct identification, please refer to the other [UK SMI categories](#).

Antimicrobial Susceptibility Testing (AST) is also beyond the scope of this document. However, for effective antibiotic stewardship, laboratories should perform AST on all clinically significant isolates, particularly in cases of poor treatment response. For further information related to AST, please refer to the other UK SMI categories.

This document addresses laboratory processes for microorganism identification and is not intended for primary healthcare guidance. For relevant information please refer to the [UK SMI Syndromic documents](#).

UK SMIs should be used in conjunction with other relevant UK SMIs.

4 Introduction

4.1 Taxonomy and characteristics

Haemophilus species

The genus *Haemophilus* is part of the family Pasteurellaceae in the order Pasteurellales (1). There are currently 8 species of the genus *Haemophilus* associated with human infection (1,2). *Haemophilus aphrophilus* and *Haemophilus paraphrophilus* have been reclassified as a single species based on multilocus sequence analysis, *Aggregatibacter aphrophilus*, which includes V-factor dependent and V-factor independent isolates. *Haemophilus segnis* has been reclassified as *Aggregatibacter segnis* (3,4). *Haemophilus influenzae* is the type species.

There are six antigenically distinct capsular types of *H. influenzae*, designated 'a' to 'f' based on the polysaccharide composition of the capsular structure. Isolates that do not express a polysaccharide capsule are referred to as non-capsulated or non-typeable (5). Before the introduction of a vaccine against serotype b (Hib), the majority of infections were caused by serotype b strains but incidence has significantly decreased following vaccination programme implementation (6). However, all types of *H. influenzae* (including non-typeable strains) can cause infections such as meningitis, bacteraemia, sepsis, otitis media and rhinosinusitis (7,8).

Other *Haemophilus* species associated with human infection are *Haemophilus aegyptius*, *Haemophilus haemolyticus*, *Haemophilus parainfluenzae*, *Haemophilus pittmaniae*, *Haemophilus paraaemolyticus*, *Haemophilus paraphrohaemolyticus* and *Haemophilus ducreyi* (9).

Haemophilus species are fastidious, Gram negative coccobacilli or rods with marked pleomorphism. They are facultatively anaerobic, non-acid-fast, non-spore forming and non-motile (2,9). All species require either or both of two growth factors for growth: haemin (factor X) and/or nicotinamide adenine dinucleotide (factor V), which can be used to aid in identification of species (9,10).

Other HACEK group of organisms

A systematic approach is used to differentiate the HACEK group of clinically encountered, morphologically similar, aerobic, and facultatively anaerobic Gram-negative rods mainly associated with endocarditis and infections from normally sterile sites. These organisms are oropharyngeal/respiratory tract commensals (11,12).

Aggregatibacter species

Aggregatibacter species are members of the family Pasteurellaceae. The genus Aggregatibacter contains 4 species, *Aggregatibacter actinomycetemcomitans*, *Aggregatibacter aphrophilus*, *Aggregatibacter segnis* and *Aggregatibacter kilianii*. The type species is *Aggregatibacter actinomycetemcomitans* (1).

A. actinomycetemcomitans has been found in endocarditis, brain abscess and urinary tract infections (3).

Aggregatibacter species are Gram-negative, non-motile, facultatively anaerobic, pleomorphic rods or coccobacilli. There is no dependence on X factor and the requirement for V factor is variable.

The species of the genus are intimately associated with humans; they are part of the human oral flora and are occasionally recovered from other body sites, including blood and brain, and as causes of infective endocarditis and abscesses.

Cardiobacterium species

The genus *Cardiobacterium* are members of the *Cardiobacteriaceae* family. The genus *Cardiobacterium* contains 2 species, *Cardiobacterium hominis* and *Cardiobacterium valvarum*. *C. hominis* is the type species (1,13). They are Gram negative, facultatively anaerobic, pleomorphic straight rods and are arranged singly, in pairs, in short chains and in rosette clusters (14).

Eikenella species

The genus *Eikenella* is part of the *Neisseriaceae* family. Currently there are 5 species within the genus *Eikenella*. The type species is *Eikenella corrodens*, which is a coloniser of the oral mucous membranes, the upper respiratory tract and possibly the gastrointestinal tract. Other species include *Eikenella exigua*, *Eikenella glucosivorans*, *Eikenella halliae*, *Eikenella loninqua* (1). *Eikenella* species are Gram negative, facultatively anaerobic (except for *E. loninqua*) small rods with occasional filaments. They are non-motile; however, some species exhibit a “twitching” motility (15,16).

Kingella species

The genus *Kingella* is in the *Neisseriaceae* family and comprises of five species, *Kingella kingae*, *Kingella denitrificans*, *Kingella potus* and *Kingella oralis*, *Kingella negevensis*, with *K. kingae* being the type species (1). *Kingella indologenes* has been transferred to a new genus and classified as *Suttonella indologenes* (17). They are Gram negative, non-motile straight rods with rounded or square ends. They occur in pairs and sometimes short chains (18).

Identification of Haemophilus species and the HACEK group of organisms

Kingella species may grow on Neisseria selective agar and therefore may be misidentified as pathogenic Neisseria species. The strain can be differentiated from Moraxella and Neisseria species by a catalase test. Most Kingella species are catalase negative; Moraxella and most Neisseria species (except *Neisseria elongata*) are catalase positive.

5 Technical information and limitations

With improvements to molecular taxonomy, species previously included in the Haemophilus genus have been reclassified into the Aggregatibacter genus (3)

Whilst no longer in the same genus, identification of these species can be difficult due to similarities in characteristics. Clinicians are encouraged to ensure they are aware of any further taxonomy changes and take this into account when interpreting laboratory results. All databases including MALDI-TOF MS, should be updated accordingly. Changes in taxonomy should be considered when using commercial identification systems.

6 Safety considerations

The section covers specific safety considerations (19-40) related to this UK SMI, and should be read in conjunction with the general [safety considerations on the RCPATH website](#).

All HACEK species are Hazard Group 3 organisms and processing of diagnostic samples should be carried out at Containment Level 2.

H. influenzae is a Hazard Group 4 organism, and in some cases the nature of the work may dictate full Containment Level 3 conditions. All laboratories should handle specimens as if potentially high risk.

H. influenzae can cause serious invasive disease, especially in young children. Invasive disease is usually caused by encapsulated strains of the organism. Laboratory acquired infections have been reported (41). The organism infects primarily by the respiratory route (inhalation), autoinoculation or ingestion in laboratory workers (42).

Laboratory procedures that give rise to infectious aerosols must be conducted in a microbiological safety cabinet.

For safety considerations for individual tests, please see [UK SMI Test Procedures documents](#)

The above guidance should be supplemented with local COSHH and risk assessments.

Compliance with postal and transport regulations is essential.

7 Target organisms

Please refer to Table 1 for all HACEK species associated with human disease.

8 Identification

Identification of Haemophilus and other HACEK species requires a combination of methods. Colonies on blood or chocolate agar may be presumptively identified by colonial morphology, microscopy, requirement for X and V factors and MALDI-TOF MS. Biochemical tests can be used in laboratories when MALDI-TOF MS is unavailable. If confirmation or further identification is required, samples are transported to reference or specialised testing laboratories.

8.1 Culture methods

Culture can be used to provide presumptive identification of HACEK organisms. Initial assessments of colonial morphology can dictate future testing when investigating potential HACEK isolates. Following presumptive identification, further techniques, including MALDI-TOF MS or biochemical tests can be used to further identify the species.

8.1.1 Bacterial growth medium

Haemophilus species require enriched media to support growth. They require either X and/or V factor. This can be added to medium unless chocolate blood agar is used (9). For the growth of *H. ducreyi* and *H. aegyptius*, growth medium should be further supplemented with growth factors, which are commercially available as a supplement (9).

All HACEK species are facultative anaerobes and grow best with 5-10% CO₂ present. The optimum growth temperature is between 35 and 37°C (9,43). HACEK species are slow growing and therefore most colonies can take between 24 and 48 hours, however *E. exigua* and *C. valarum* can take up to 72 hours to become visible (16,44).

Primary isolation media

For Haemophilus species, incubation for 24-48 hours with enriched 5% chocolatised sheep blood agar at 35 to 37°C with 5 to 10% CO₂ is preferred (45). Blood agar can be used instead of chocolate agar, providing free V and X factor are supplemented.

Other HACEK species can be incubated for 24-48 hours on either chocolate blood agar or blood agar at 35-37°C with 5-10% CO₂ present (43).

Selective media

Haemophilus selective agar is commercially available and contains horse blood and antibiotics (kanamycin and vancomycin). If not already present, bacitracin can be added to inhibit Neisseria species. Cultures should be incubated at 35-37°C with 5-10% CO₂ for 24-48 hours (9).

Selective media for *A. actinomycetemcomitans* is commercially available. Samples should be incubated at 35-37°C for 18-24 hours under anaerobic conditions (43).

8.1.2 Colonial appearance

Colonial appearance varies significantly with species, however generally:

- Haemophilus species produce colonies that are flat, convex and grey-white on blood agar (10)
- Aggregatibacter species produce colonies that are greyish-white/yellow, granular and rough (46)
- Cardiobacterium species produce smooth, convex and opaque colonies (14)
- Eikenella species produce colonies that may corrode the agar (15)
- Kingella species produce either spreading/corroding colonies or smooth, convex colonies (18)

For detailed descriptions of each species refer to section 8.2, Table 1.

8.2 Microscopic appearance

8.2.1 Gram stain

Please refer to [UK SMTTP 39 - Staining procedures](#).

All HACEK species are Gram negative; however, some species may stain weakly.

- Haemophilus species are small-medium sized pleomorphic rods; however, spheres and coccobacilli can be seen (10)
- Aggregatibacter species tend to be rod-shaped, but coccobacilli can also be observed (46)
- Cardiobacterium species are straight rods with rounded ends and occasional long filaments (14)
- Eikenella species are usually straight, unbranched rods with rounded edges (15)
- Kingella species are straight rods with rounded/square ends. *K. kingae* does not Gram stain well (18)

Identification of Haemophilus species and the HACEK group of organisms

For information on the microscopic appearance of individual species refer to table 1 below.

Table 1: Microscopic and Colonial appearance of HACEK species (9,10,16,44,46-53)

Please note that the information in this table provides general characteristics of colony appearance and can vary among different strains and culture conditions.

Species	Appearance	Additional Comments
<i>H. influenzae</i>	Small, regular rods that can be mixed with coccobacilli. Colonies are smooth, low, convex, greyish, translucent. Encapsulated strains can appear mucoid. Non-encapsulated strains produce small, buff colonies.	In 24 hours colonies grow to 1-2mm in diameter. Indole producing strains have an amine-like odour.
<i>H. aegyptius</i>	Slow-growing colonies. Colonies produced are smooth, low, convex and translucent.	Grow to 0.5mm diameter in 48 hours
<i>H. ducreyi</i>	Slender rods. Colonies are small, flat, smooth and grey. Larger colonies are sometimes seen mixed with smaller colonies.	Grows poorly. Can take 3-5 days to become visible. Can be surrounded by small zone of β -haemolysis.
<i>H. pittmaniae</i>	Small pleomorphic rods with occasional filamentous forms. Colonies are convex and grey-white.	Grow to 1-2mm diameter in 24 hours.
<i>H. parainfluenzae</i>	Small pleomorphic rods interspersed with filamentous forms. Colonies are off-white to yellow colored. Colony appearance can vary. They can be flat and smooth or granular or wrinkled.	Grow to 1-2mm diameter in 24 hours. Some strains show β haemolysis. Colony appearance may change with age.
<i>H. haemolyticus</i>	Small, regular rods or spheres with occasional filamentous forms. Colonies are translucent, smooth, and convex.	Colonies grow to 0.5-1.5mm diameter after 24 hours. Produce a clear zone of β -haemolysis.
<i>H. parahaemolyticus</i>	Small, regular rods with occasional filamentous forms. Smooth colonies similar to <i>H. parainfluenzae</i> .	Produce zone β -haemolysis.
<i>H. paraphaemolyticus</i>	Small rods. Colonies similar to <i>H. haemolyticus</i> .	None
<i>A. actinomycetemcomitans</i>	Small pleomorphic rods. Rough, tenacious colonies with an internal, opaque pattern.	Colonies grow to diameter of 1-2mm after 48 hours. Colonies can be sticky if slime is produced.
<i>A. aphrophilus</i>	Short regular rods with occasional filamentous forms. Colonies are convex, opaque, granular, and yellowish.	None

Identification of Haemophilus species and the HACEK group of organisms

Species	Appearance	Additional Comments
<i>A. segnis</i>	Small pleomorphic rods, sometimes with irregular filamentous forms. Colonies are slow growing. They are smooth, granular, convex, greyish-white, and opaque.	None
<i>A. kilianii</i>	Short regular rods with occasional filamentous forms. Supplemented with CO ₂ colonies are granular, yellowish, and opaque. Without CO ₂ colonies are small with larger colonies interspersed.	None
<i>C. hominis</i>	Small colonies produced unless in a humid atmosphere. Colonies are circular, smooth, moist and opaque.	Colonies can cause some α -haemolysis.
<i>E. corrodens</i>	Colonies are small with a moist clear centre surrounded by flat spreading growth. Pitting of the medium can occur.	Non-haemolytic. Older cultures can turn yellow.
<i>K. denitrificans</i>	Colonies are small and translucent. They may show pitting of the medium.	None
<i>K. kingae</i>	Colonies produce small depressions. They have a central pailla and spreading growth with granular zones surrounding. Colonies can also be small delicate, translucent/opaque.	Colonies can cause β -haemolysis.
<i>K. oralis</i>	Colonies are round with irregular borders. They are flat to umbonate with a granular periphery.	None
<i>K. potus</i>	Colonies are circular, convex, and smooth. They are often yellow pigmented.	Non-haemolytic.
<i>K. negevensis</i>	Colonies are round and smooth. They can be pale yellow in colour.	Colonies are β -haemolytic.

8.3 Matrix Assisted Laser Desorption/Ionisation - Time of Flight Mass Spectrometry (MALDI-TOF MS)

MALDI-TOF MS is used as the primary method for the identification of HACEK species in diagnostic laboratories. Therefore, it is important that this method is appropriately validated, manufacturer instructions carefully followed, available database updates installed and reviewed, and the use of an extraction step that can contribute to a more reliable species identification should be considered.

MALDI-TOF MS is used for the identification of several *Haemophilus* species, including *H. influenzae*, *H. parainfluenzae*, *H. parahaemolyticus* (54,55). Databases

Identification of Haemophilus species and the HACEK group of organisms

that are used only for research may include other *Haemophilus* species including *H. haemolyticus*, however it should be noted that MALDI-TOF MS can incorrectly identify *H. haemolyticus* isolates as *H. influenzae* or *H. parainfluenzae* (56). In the case of suspected misidentification, results should be interpreted carefully, and further biochemical tests or molecular methods are recommended.

This technique accurately identifies members of the other HACEK genera, despite their fastidious nature (55,57). MALDI-TOF MS is effective for identification of *Aggregatibacter* species, *C. hominis*, *E. corrodens* and *K. kingae* (58). Some species, including *A. killianii*, *K. negevensis* and any new species resulting from taxonomy changes may not be included in the analyser databases. Laboratories are encouraged to check the MALDI-TOF MS databases used if these organisms are suspected. Biochemical testing is recommended for species not represented in the MALDI-TOF MS databases.

8.4 Further identification

8.4.1 Biochemical tests and commercial identification systems

Biochemical tests are no longer routine in laboratories but are used in cases when MALDI-TOF MS is unavailable or when MALDI-TOF MS results are inconclusive. Discrepancies in test results should be referred to the appropriate reference or specialist laboratories for further testing. Refer to the manufacturer's guidance or the relevant chapters in the *Manual of Clinical Microbiology* book (9,43) for biochemical properties of individual HACEK species. Algorithms B and C contain examples of biochemical tests that may be used to differentiate between HACEK organisms.

Several commercial identification systems that use biochemical or enzymatic substrates are available for identification of *Haemophilus* species. The manufacturer's instructions should be followed precisely when using these kits. In many cases, the commercial identification system may not reflect recent changes in taxonomy.

X and V factor Test

Please refer to [UK SMI TP 38 – X and V Factor Test](#)

Haemophilus species have a requirement for V factor, which can be helpful in species identification. X and V factor test can provide initial information on the species. Porphyrin tests can identify X factor dependent species. Negative porphyrin tests suggest X factor dependence. For X & V factor requirements of the relevant *Haemophilus* species see table 2 below.

The use of chocolate agar is preferable for species that require X and V factor for growth rather than blood agar or blood containing medium because of risk of carryover

Identification of Haemophilus species and the HACEK group of organisms

of X factor. The X and V factor testing could also be done using a basic nutrient agar, but for which the X and V discs have been validated in case it had trace factors that could influence the results. Manufacturers' instructions should be followed when performing this test.

Please note that sometimes the X and V factor tests can give false V dependent results if incubated in CO₂ (59).

Table 2: Summary of X and V test results (9)

Organism	X factor	V factor	β-haemolysis
<i>H. influenzae</i> ^a	+	+	-
<i>H. parainfluenzae</i>	-	+	-
<i>H. haemolyticus</i> ^b	+	+	+
<i>H. parahaemolyticus</i>	-	+	+
<i>H. paraphrohaemolyticus</i>	-	+	+
<i>H. aegyptius</i>	+	+	-
<i>H. pittmaniae</i>	-	+	+
<i>H. ducreyi</i>	+	-	-

^a *H. aegyptius* is indistinguishable from *H. influenzae* biotype III in normal laboratory tests.

^b Traditionally described as β-haemolytic on horse blood agar, but non-haemolytic strains exist (60)

8.4.2 Serotyping *H. influenzae* with commercial type-specific antisera and PCR

If *H. influenzae* is detected, serotyping should be performed using slide agglutination or PCR testing. The presence of capsule polysaccharide can be detected by slide agglutination using commercial antisera. If positive, the individual serotype (a to f) can also be determined using antisera. Slide agglutination can sometimes generate ambiguous results and so the capsule type can be confirmed using multiple PCRs directed at targets within the capsule gene operon (61,62).

Some multi-species meningitis latex agglutination detection kits include antiserum against *H. influenzae* serotype b alone because of its historical dominance in causing meningitis and its relevance in detecting vaccine failures. However, it should be noted that not all latex agglutination detection kits are suitable for use on bacterial suspensions of *H. influenzae* (according to the manufacturer's instructions).

8.4.3 Molecular Methods

Identification of Haemophilus species and the HACEK group of organisms

Molecular techniques have made identification of many species more rapid and precise than is possible with phenotypic techniques. However, some of these methods are difficult to implement for routine bacterial identification in a clinical laboratory and may be better sourced from a reference laboratory.

Other tests such as NAATs have been developed to identify *H. influenzae* and *H. parainfluenzae* in clinical specimens and some have been incorporated into commercial multi-pathogen detection systems (63). NAATs have been used to identify *H. ducreyi* in clinical specimens. A commercial multiplex PCR assay has been developed that permits the simultaneous amplification of DNA targets from *H. ducreyi*, *Trepanemal pallidum*, and Herpes Simplex Virus types 1 and 2 directly from genital ulcer specimens (64).

A genotypic identification method, 16S rRNA gene sequencing has been used for better discrimination of closely related species such as *C. hominis* and *C. valvarum* (44,65). It has equally been used for identifying Haemophilus and Aggregatibacter species (60).

Next Generation Sequencing

Whilst currently limited to reference laboratories, Next Generation Sequencing (NGS) could become more common in clinical laboratories. Metagenomic NGS has been used to confirm identification of *A. segnis* and *H. influenzae* (66,67). NGS provides a quick and accurate means of identifying pathogens that could be potentially beneficial for routine diagnostics in the future (68).

9 Storage

For short term storage of HACEK species, isolates should be kept viable on chocolate blood agar supplemented with 5-7% CO₂ at 35-37°C (9).

For long term storage of HACEK species, isolates should be frozen at -80°C in a cryoprotective solution such as glycerol or trypticase soy broth (43,69).

If required, save pure isolates on a chocolate agar slope for referral to the reference laboratory.

10 Reporting

10.1 Infection Specialist

Inform the medical microbiologist of all positive cultures from normally sterile sites.

Invasive *H. Influenzae* should be reported for surveillance purposes.

Certain clinical conditions must be notified to the laboratory associated infection specialist. Typically, these will include:

- Facial cellulitis
- Septic arthritis
- Osteomyelitis
- Epiglottitis, pneumonia, mastoiditis or empyema thoracis

Follow local protocols for reporting to clinician.

10.2 Routine identification

Initially appropriate growth characteristics, colonial appearance and Gram stain of the culture are indicative of a fastidious organism. Identification is made using MALDI-TOF MS or where not available using biochemical methods and appropriate X and V factors.

10.3 Confirmation of identification

Following identification serotyping of *H. Influenzae* can be obtained from the reference or specialist laboratory.

For confirmation and identification please see [Specialist and reference microbiology: laboratory tests and services page on GOV.UK](#) for reference laboratory user manuals and request forms.

10.4 Health Protection Team (HPT)

Refer to local agreements in devolved administrations.

10.5 UK Health Security Agency

Refer to current guidelines on Second Generation Surveillance System (SGSS) reporting (35).

10.6 Infection prevention and control team

N/A

11 Referral to reference or specialist laboratories

If isolates are being transported to further laboratories for testing, ensure specimen is placed in a sealed container within appropriate packaging, following all relevant transport regulations. If required, save pure isolate on a chocolate agar slope for referral to the reference laboratory.

Isolates of *H. influenzae* from normally sterile sites should be sent to the Vaccine Preventable Bacteria Section, Respiratory and Vaccine Preventable Bacteria Reference Unit (RVPBRU), UK Health Security Agency (UKHSA) for confirmation and typing.

For information on the tests offered, turnaround times, transport procedure and the other requirements of the reference or specialist laboratory [see user manuals and request forms](#)

Organisms with unusual/unexpected resistance, associated with a laboratory/clinical problem or an anomaly that requires investigation should be sent to the appropriate reference laboratory.

Contact appropriate reference or specialist laboratory for information on the tests available, turnaround times, transport procedure and any other requirements for sample submission:

[England](#)


[Wales](#)

[Scotland](#)

[Northern Ireland](#)

Consultation between 07 May 2024 to 24 May 2024


Algorithm A: Identification of HACEK Species



This flowchart is for guidance only.

Algorithm B: Identification of Haemophilus species


This flowchart provides a summary of biochemical tests to supplement algorithm A.



This flowchart is for guidance only.

Algorithm C: Identification of other HACEK organisms

This flowchart provides a summary of biochemical tests to supplement algorithm A.



*variable results

If required refer to appropriate reference or specialist laboratory for confirmation testing

This flowchart is for guidance only.

References

An explanation of the reference assessment used is available in the [scientific information section on the UK SMI website](#).

1. Parte AC and others. List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZ. *Int J Syst Evol Microbiol* 2020: volume 70, issue 11, pages 5607-12. <https://doi.org/10.1099/ijsem.0.004332>
2. Cooke FJ, Slack MPE. 183 - Gram-Negative Coccobacilli. In: Cohen JL, Powderly WG, Opal SM, editors. *Infectious Diseases (Fourth Edition)*. Elsevier; 2017. pages. 1611-27.e1.
3. Norskov-Lauritsen N, Kilian M. Reclassification of *Actinobacillus actinomycetemcomitans*, *Haemophilus aphrophilus*, *Haemophilus paraphrophilus* and *Haemophilus segnis* as *Aggregatibacter actinomycetemcomitans* gen. nov., comb. nov., *Aggregatibacter aphrophilus* comb. nov. and *Aggregatibacter segnis* comb. nov. and emended description of *Aggregatibacter aphrophilus* to include V factor-dependent and V factor-independent isolates. *International Journal of Systematic and Evolutionary Microbiology* 2006: volume 56, issue Pt 9, pages 2135-46. **A, II**
4. Chien Y-C and others. Clinical characteristics of bacteremia caused by *Haemophilus* and *Aggregatibacter* species and antimicrobial susceptibilities of the isolates. *Journal of Microbiology, Immunology and Infection* 2021: volume 54, issue 6, pages 1130-8. <https://doi.org/10.1016/j.jmii.2020.12.002>
5. Wen S and others. Molecular epidemiology and evolution of *Haemophilus influenzae*. *Infection, Genetics and Evolution* 2020: volume 80, pages 104205. <https://doi.org/10.1016/j.meegid.2020.104205>
6. Park JJ and others. Estimating the global and regional burden of meningitis in children caused by *Haemophilus influenzae* type b: A systematic review and meta-analysis. *Journal of Global Health* 2022: volume 12. 10.7189/jogh.12.04014
7. Ulanova M, Tsang RSW. *Haemophilus influenzae* serotype a as a cause of serious invasive infections. *The Lancet Infectious Diseases* 2014: volume 14, issue 1, pages 70-82. [https://doi.org/10.1016/S1473-3099\(13\)70170-1](https://doi.org/10.1016/S1473-3099(13)70170-1)
8. Bertran M and others. Trends in invasive *Haemophilus influenzae* serotype a disease in England from 2008–09 to 2021–22: a prospective national surveillance study. *The Lancet Infectious Diseases* 2023: volume 23, issue 10, pages 1197-206. [https://doi.org/10.1016/S1473-3099\(23\)00188-3](https://doi.org/10.1016/S1473-3099(23)00188-3)

Identification of Haemophilus species and the HACEK group of organisms

9. Manual of Clinical Microscopy Carroll KCP, M.A; Haemophilus Washington DC: ASM Press; 2023. 10.1128/9781683670438.MCM.ch38
10. Nørskov-Lauritsen N. Haemophilus. Bergey's Manual of Systematics of Archaea and Bacteria; 2021. pages. 1-22.
11. Khaledi M and others. Infective endocarditis by HACEK: a review. J Cardiothorac Surg 2022: volume 17, issue 1, pages 185. 10.1186/s13019-022-01932-5
12. Chambers ST and others. HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. PLOS ONE 2013: volume 8, issue 5, pages e63181. 10.1371/journal.pone.0063181
13. Han XY and others. Endocarditis with ruptured cerebral aneurysm caused by *Cardiobacterium valvarum* sp. nov. Journal of Clinical Microbiology 2004: volume 42, issue 4, pages 1590-5. **A, IV**
14. Paster BJ, Dewhirst FE. *Cardiobacterium*. Bergey's Manual of Systematics of Archaea and Bacteria; 2015. pages. 1-6.
15. Bottone EJ and others. *Eikenella*. Bergey's Manual of Systematics of Archaea and Bacteria; 2015. pages. 1-11.
16. Bernard KA and others. Description of *Eikenella halliae* sp. nov. and *Eikenella longinqua* sp. nov., derived from human clinical materials, emendation of *Eikenella exigua* Stormo et al. 2019 and emendation of the genus *Eikenella* to include species which are strict anaerobes. Int J Syst Evol Microbiol 2020: volume 70, issue 5, pages 2167-78. **B, II** 10.1099/ijsem.0.004150
17. Dewhirst FE and others. Transfer of *Kingella indologenes* (Snell and Lapage 1976) to the genus *Suttonella* gen. nov. as *Suttonella indologenes* comb. nov.; transfer of *Bacteroides nodosus* (Beveridge 1941) to the genus *Dichelobacter* gen. nov. as *Dichelobacter nodosus* comb. nov.; and assignment of the genera *Cardiobacterium*, *Dichelobacter*, and *Suttonella* to *Cardiobacteriaceae* fam. nov. in the gamma division of Proteobacteria on the basis of 16S rRNA sequence comparisons. International Journal of Systematic Bacteriology 1990: volume 40, issue 4, pages 426-33. **B, III**
18. Weyant RS. *Kingella*. Bergey's Manual of Systematics of Archaea and Bacteria; 2015. pages. 1-8.
19. Advisory Committee on Dangerous Pathogens. The Approved List of Biological Agents. Health and Safety Executive 2021. pages 1-39. **++**
20. British Standards Institution (BSI). BS EN12469 - Biotechnology - performance criteria for microbiological safety cabinets 2000. **A, V**

Identification of Haemophilus species and the HACEK group of organisms

21. British Standards Institution (BSI). BS 5726:2005 - Microbiological safety cabinets. Information to be supplied by the purchaser and to the vendor and to the installer, and siting and use of cabinets. Recommendations and guidance. 2005. pages 1-14. **A, V**
22. Centers for Disease Control and Prevention. Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories. MMWR Surveill Summ 2012: volume 61, pages 1-102. **B, IV**
23. Department for Transport and others. Transport of infectious substances UN2814, UN2900 and UN3373 Guidance note number 17/2012 (revision 7). 2013. **++**
24. Department of Health. Health Protection Legislation (England) Guidance. pages 1-112. 2010. **A, VI**
25. Gizzie N, Adukwu E. Evaluation of Liquid-Based Swab Transport Systems against the New Approved CLSI M40-A2 Standard. J Clin Microbiol 2016: volume 54, issue 4, pages 1152-6. **2+** 10.1128/JCM.03337-15
26. Health and Safety Executive. Managing risks and risk assessment at work (accessed 28/07/2021). <https://www.hse.gov.uk/simple-health-safety/risk/index.htm>. **++**
27. Health and Safety Executive. Safe use of pneumatic air tube transport systems for pathology specimens. 2009. **++**
28. Health and Safety Executive. Control of Substances Hazardous to Health Regulations. The Control of Substances Hazardous to Health Regulations 2002 (as amended). Approved Code of Practice and guidance L5 (sixth edition). HSE Books. 2013. **++**
29. Health and Safety Executive. Risk assessment: A brief guide to controlling risks in the workplace. HSE. 2014. **++**
30. Health and Safety Executive, Advisory Committee on Dangerous Pathogens. Management and operation of microbiological containment laboratories. HSE. 2019. **++**
31. Health Services Advisory Committee. Safe Working and the Prevention of Infection in Clinical Laboratories and Similar Facilities. HSE Books 2003. **A, V**
32. Home Office. Public Health Act (Northern Ireland) 1967 Chapter 36. 1967. **A, VI**
33. Home Office. Anti-terrorism, Crime and Security Act. 2001. **A, V**

Identification of Haemophilus species and the HACEK group of organisms

34. Official Journal of the European Communities. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices 1998. pages 1-37. **A, V**
35. Public Health England. Laboratory reporting to Public Health England: a guide for diagnostic laboratories. PHE. 2020. pages 1-31. **++**
36. Scottish Government. Public Health (Scotland) Act. 2008. **A, VI**
37. The Royal College of Pathologists. The retention and storage of pathological records and specimens (5th edition). pages 1-59. 2015. **++**
38. The Welsh Assembly Government. Health Protection Legislation (Wales) Guidance. 2010. **A, V**
39. Tyrrell KL and others. Comparison of the Copan eSwab System with an Agar Swab Transport System for Maintenance of Fastidious Anaerobic Bacterium Viability. J Clin Microbiol 2016: volume 54, issue 5, pages 1364-7. **2+**
10.1128/JCM.03246-15
40. World Health Organization. Guidance on regulations for the transport of infectious substances 2019-2020. WHO. 2019. **++**
41. Collins CH, Kennedy D.A. Laboratory acquired infections. In: Woburn MA, editor. Laboratory acquired infection: history, incidence, causes and prevention. 4 ed.; 1999. pages. 1-37. **B, IV**
42. Jacobson JT and others. Infections acquired in clinical laboratories in Utah. Journal of Clinical Microbiology 1985: volume 21, issue 4, pages 486-9. **B, IV**
43. Manual of Clinical Microbiology Carroll KCP, M.A; Aggregatibacter, Capnocytophaga, Eikenella, Kingella, Pasteurella and Other Fastidious or Rarely Encountered Gram-Negative Rods Washington DC: ASM Press; 2023. 10.1128/9781633670438.MCM.ch37
44. Chen M and others. Cardiobacterium valvarum infective endocarditis and phenotypic/molecular characterization of 11 Cardiobacterium species strains. Journal of Medical Microbiology 2011: volume 60, issue Pt 4, pages 522-8. **A, IV**
jmm.0.025353-0 [pii];10.1099/jmm.0.025353-0 [doi]
45. Harris TM and others. Culture of non-typeable Haemophilus influenzae from the nasopharynx: Not all media are equal. Journal of Microbiological Methods 2017: volume 137, pages 3-5. <https://doi.org/10.1016/j.mimet.2017.03.012>
46. Nørskov-Lauritsen N. Aggregatibacter. Bergey's Manual of Systematics of Archaea and Bacteria; 2021. pages. 1-9.

Identification of Haemophilus species and the HACEK group of organisms

47. Slotnick IJD, M. Further characterization of an unclassified group of bacteria causing endocarditis in man: *Cardiobacterium hominis* gen. et sp. n. *Antonie Van Leeuwenhoek* 1964: volume 30, pages 261-72. **B, III**
48. Dewhirst FE and others. *Chromobacterium*, *Eikenella*, *Kingella*, *Neisseria*, *Simonsiella*, and *Vitreoscilla* Species Comprise a Major Branch of the Beta Group Proteobacteria by 16S Ribosomal Ribonucleic Acid Sequence Comparison: Transfer of *Eikenella* and *Simonsiella* to the Family *Neisseriaceae* (emend.). *International Journal of Systematic Bacteriology* 1989: volume 39, issue 3, pages 258-66. **B, II** <https://doi.org/10.1099/00207713-39-3-258>
49. Hollis DG and others. Emended description of *Kingella denitrificans* (Shall and Lapage 1976): correction of the maltose reaction. *Journal of Clinical Microbiology* 1983: volume 18, issue 5, pages 1174-6. **B, II**
50. Henriksen SD, Bovre K. Transfer of *Moraxella kingae* Henriksen and Bovre to the Genus *Kingella* gen. nov. in the family *Neisseriaceae*. *International Journal of Systematic Bacteriology* 1976: volume 26, issue 4, pages 447-50. **B, III**
51. Dewhirst FE and others. Phylogeny of species in the family *Neisseriaceae* isolated from human dental plaque and description of *Kingella oralis* sp. nov [corrected]. *International Journal of Systematic Bacteriology* 1993: volume 43, issue 3, pages 490-9. **A, II**
52. Lawson PA and others. Description of *Kingella potus* sp. nov., an organism isolated from a wound caused by an animal bite. *Journal of Clinical Microbiology* 2005: volume 43, issue 7, pages 3526-9. **B, II** 43/7/3526 [pii];10.1128/JCM.43.7.3526-3529.2005 [doi]
53. El Houmami N and others. Isolation and characterization of *Kingella negevensis* sp. nov., a novel *Kingella* species detected in a healthy paediatric population. *Int J Syst Evol Microbiol* 2017: volume 67, issue 7, pages 2370-6. **A, III** 10.1099/ijsam.0.001957
54. Branda JA and others. Multicenter validation of the VITEK MS v2.0 MALDI-TOF mass spectrometry system for the identification of fastidious gram-negative bacteria. *Diagnostic Microbiology and Infectious Disease* 2014: volume 78, issue 2, pages 129-31. <https://doi.org/10.1016/j.diagmicrobio.2013.08.013>
55. Almuzara M and others. Performance of MALDI-TOF mass spectrometry for the identification of the HACEK group and other fastidious gram-negative rods. *Open Microbiology Journal* 2019: volume 13, issue 1, pages 216-21-21. 10.2174/1874285801913010125
56. Nürnberg S and others. Discriminative Potential of the Vitek MS In Vitro Diagnostic Device Regarding *Haemophilus influenzae* and *Haemophilus haemolyticus*. *Journal of Clinical Microbiology* 2020: volume 58, issue 9, pages 10.1128/jcm.00278-20. 10.1128/jcm.00278-20

57. Powell Eleanor A and others. Application of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Identification of the Fastidious Pediatric Pathogens *Aggregatibacter*, *Eikenella*, *Haemophilus*, and *Kingella*. *Journal of Clinical Microbiology* 2020: volume 51, issue 11, pages 3862-4. 10.1128/jcm.02233-13
58. Couturier MR and others. Identification of HACEK clinical isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Journal of Clinical Microbiology* 2011: volume 49, issue 3, pages 1104-6. **A, III** JCM.01777-10 [pii];10.1128/JCM.01777-10 [doi]
59. Jones AM. *Haemophilus influenzae* and *H. parainfluenzae*: the influence of media and CO² on differentiation using X, V and XV discs. *Medical Laboratory Sciences* 1982: volume 39, issue 2, pages 189-91. **B, III**
60. Nørskov-Lauritsen N. Classification, identification, and clinical significance of haemophilus and aggregatibacter species with host specificity for humans. *Clinical Microbiology Reviews* 2014: volume 27, issue 2, pages 214-40. **A, III** 27/2/214 [pii];10.1128/CMR.00103-13 [doi]
61. Falla TJ and others. PCR for capsular typing of *Haemophilus influenzae*. *J Clin Microbiol* 1994: volume 32, issue 10, pages 2382-6. **B, III**
62. Wroblewski D and others. Utilization of a real-time PCR approach for *Haemophilus influenzae* serotype determination as an alternative to the slide agglutination test. *Mol Cell Probes* 2013: volume 27, issue 2, pages 86-9. **B, III** 10.1016/j.mcp.2012.11.003
63. Tian GZ and others. Rapid Detection of *Haemophilus influenzae* and *Haemophilus parainfluenzae* in Nasopharyngeal Swabs by Multiplex PCR. *Biomedical and Environmental Sciences* 2012: volume 25, issue 3, pages 367-71. <https://doi.org/10.3967/0895-3988.2012.03.016>
64. Orle KA and others. Simultaneous PCR detection of *Haemophilus ducreyi*, *Treponema pallidum*, and herpes simplex virus types 1 and 2 from genital ulcers. *Journal of Clinical Microbiology* 1996: volume 34, issue 1, pages 49-54. **B, II**
65. Hoffman MJ and others. Prosthetic valve/conduit infection caused by *Cardiobacterium valvarum*. *Infection* 2010: volume 38, issue 3, pages 245-6. **B, IV** 10.1007/s15010-010-0004-5 [doi]
66. Morsli M and others. *Haemophilus influenzae* Meningitis Direct Diagnosis by Metagenomic Next-Generation Sequencing: A Case Report. 2021. 10.3390/pathogens10040461

Identification of Haemophilus species and the HACEK group of organisms

67. Guo X and others. Endocarditis due to *Aggregatibacter* *Segnis*: a rare case report. *BMC Infect Dis* 2023: volume 23, issue 1, pages 309. 10.1186/s12879-023-08231-x
68. Gwinn M and others. Next-Generation Sequencing of Infectious Pathogens. *Jama* 2019: volume 321, issue 9, pages 893-4. 10.1001/jama.2018.21669
69. Villa L and others. Long term storage of fastidious bacteria (*Neisseria* spp. and *Haemophilus* spp.) with swab preservation at -80 °C. *J Microbiol Methods* 2020: volume 175, pages 105969. 10.1016/j.mimet.2020.105969

Consultation between 07 May 2024 to 24 May 2024